Vimarsana
Biggest News Aggregation in the World

Page 4 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Brokerages Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $5.33 - Vimarsana News

Brokerages Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $5.33

Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price […]

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement - Vimarsana News

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024,...

Sector Update: Health Care -December 19, 2023 at 03:28 pm EST - Vimarsana News

Sector Update: Health Care -December 19, 2023 at 03:28 pm EST

-- Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index adding 0.4% and the Health Care Select Sector SPDR Fund up 0.5%. The iShares Biotechnology ETF rose 1.4%. In...

Related Topics:
Compugen Ltd
Compugen joins a $848M collaboration with Gilead - Vimarsana News

Compugen joins a $848M collaboration with Gilead

Compugen Ltd. has entered another collaboration, this time exclusively licensing a preclinical antibody program against an IL-18 binding protein with Gilead Sciences Inc. Compugen will handle ongoing preclinical development and a phase I study of COM-503 to treat tumors, then Gilead receives to sole right to further continue developing the asset. Compugen is getting an up-front $60 million and is eligible for a $30 million milestone payment should the IND clear in 2024. Compugen also is eligible for $758 million in development, regulatory and commercial milestones, putting the deal value at $8...

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program - Vimarsana News

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody ...